CANF EBITDA Margin
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · EBITDA Margin
CANF EBITDA Margin
Latest reported-2402.47%period ending
CANF TTM EBITDA Margin (-812.23% → -2402.47%)
TTM ebitda margin
High-resolution chart · PNG
CANF ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -2,402.4691% | |
| -2,426.6667% | |
| -2,450.8642% | |
| -1,951.3988% | |
| -1,590.1782% | |
| -1,379.9024% | |
| -1,205.1926% | |
| -1,221.2691% | |
| -1,167.1289% | |
| -1,066.4184% | |
| -1,100.9758% | |
| -1,201.2102% | |
| -1,278.3733% | |
| -1,301.4358% | |
| -1,244.7532% | |
| -1,349.7553% | |
| -1,384.8381% | |
| -1,431.5385% | |
| -1,503.9273% | |
| -1,538.7985% | |
| -1,483.9921% | |
| -1,677.77% | |
| -1,843.6435% | |
| -1,539.3168% | |
| -726.0309% | |
| -606.4992% | |
| -449.6801% | |
| -504.838% | |
| -224.0086% | |
| -179.187% | |
| -160.3877% | |
| -198.1607% | |
| -482.695% | |
| -604.4935% | |
| -1,019.1345% | |
| -844.4041% | |
| -3,637.9376% | |
| -4,028.0505% | |
| -4,098.8686% | |
| -2,685.8299% | |
| -2,625.0233% | |
| -2,377.2983% | |
| -2,724.9746% | |
| -4,225.3705% | |
| -6,722.2165% | |
| -4,576.6275% | |
| -2,144.1699% | |
| -1,368.5233% | |
| -978.4012% | |
| -859.7341% | |
| -812.2331% |